A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs MABp1 (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- 27 Feb 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2017 Primary endpoint has been met. (The efficacy of MABp1 in patients with moderate to severe HS), as reported in a XBiotech media release.
- 09 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.